



DELMAR PHARMACEUTICALS BC LTD.

Suite 115 - 887 Great Northern Way
Vancouver, British Columbia
Canada V5T 4T5

Phone: (604) 629-5989
E-Mail: info@delmarpharma.com
Web Site: www.delmarpharma.com

Management: Jeffrey Bacha, Co-founder, President & CEO; Dennis Brown, PhD, Co-founder; William Garner, MD, Co-founder

Company Launched: April 2010

Financing to Date: Undisclosed

Investors: Founders

Partners/Alliances: NA

Industry Segment: Biotechnology

Business: DelMar Pharmaceuticals BC Ltd. will commercialize known drugs for orphan cancer indications, starting with a small molecule compound that had demonstrated anti-cancer activity in previous NCI studies. VAL-083 has been marketed in China for 20 years for leukemia and lung cancer. DelMar Pharma will develop it initially for glioblastoma multiforme.

NEOGRAFT TECHNOLOGIES INC.

470 Constitution Drive
Taunton, MA 02780

Phone: (508) 802-4122
E-Mail: info@neograftinc.com
Web Site: www.neograftinc.com

Management: Jon McGrath, President & CEO; Steve Linhares, VP of Quality, Clinical & Regulatory; Mohammed El-Kurdi, PhD, Co-founder & Director, Science & Engineering; Lorenzo Soletti, PhD, Co-founder & Director, Technology Development

Company Launched: December 2010

Financing to Date: \$5 million

Investors: Private investors

Partners/Alliances: University of Pittsburgh

Industry Segment: Cardiovascular Devices

Business: Neograft Technologies Inc. hopes to combat saphenous vein graft failure in CABG patients with *AngioShield*, an electrospun polymer that creates a structural support layer surrounding the vein that mechanically strengthens it against overdistension from arterial pressure.

PEPTIVIR INC.

12635 East Montview
Boulevard
Suite 127
Aurora, CO 80045

Phone: (720) 859-4046
E-Mail: richard.duke@cid4.com
Web Site: www.peptivir.com

Management: Richard C. Duke, PhD, Chairman & Acting CEO; Robert S. Hodges, PhD, Founding Scientist, President, & Acting Director of Peptide Chemistry; Kathryn V. Holmes, PhD, Founding Scientist & Acting Director of Virology; Kevin Smith, Acting CFO

Company Launched: July 2010

Financing to Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: NA

Industry Segment: Biotechnology

Business: PeptiVir Inc. will develop and commercialize a conformationally constrained, synthetic peptide-based vaccine platform for the prevention of viral diseases. The company thinks its lead candidate, PVI-1000, has the potential to be a universal influenza vaccine that could lead to sustained protection against multiple seasonal and pandemic strains.

VISIONARY PHARMACEUTICALS INC.

11555 Sorrento Valley Road #A
San Diego, CA 92121

Phone: (858) 335-8120
E-Mail: gordon@visionarypharmaceuticals.com
Web Site: www.visionarypharmaceutical.com

Management: Gordon R. Alton, PhD, President & CEO; Ayse Batova, PhD, VP of Biology; Louis Tommasino, CFO

Company Launched: July 2010

Financing to Date: Undisclosed seed funding

Investors: Private Investors

Partners/Alliances: NA

Industry Segment: Biotechnology

Business: Visionary Pharmaceuticals Inc. will use its proprietary *BindingSIGHTs* computational technology platform and *MANIFOLD* virtual compound library to develop small molecule antagonists of nuclear orphan receptor ROR for inflammatory diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, and COPD. The start-up also has a cancer metabolism program.